Cassava Sciences Posts Q2 Loss on Pivot

Cassava Sciences (NASDAQ:SAVA), a neuroscience drug developer, released its second-quarter 2025 results on August 14, 2025, illustrating a significant transformation in its business focus and financial results. The company shifted its lead drug, simufilam, from Alzheimer’s disease to Tuberous Sclerosis Complex (TSC)-related epilepsy after terminating its Alzheimer’s program. The company reported a net loss of $44.2 million (GAAP) for Q2 2025, down sharply from net income of $6.2 million (GAAP) in Q2 2024, reflecting substantial legal expenses. There were no Wall Street consensus estimates available for comparison, as the company generates no product sales. The quarter marks a reset for the business, with operational and legal expenses still well above its cash inflows as it repositions for future growth in a new therapeutic area.Cassava Sciences is a clinical-stage biotechnology firm developing novel treatments for central nervous system (CNS) diseases. Its main asset, simufilam, is a proprietary oral drug that initially targeted Alzheimer’s disease. Following disappointing clinical trial results and an inability to meet primary endpoints, the company terminated its Alzheimer’s program in 2025.Now, Cassava Sciences is focusing on TSC-related epilepsy, a rare neurological condition affecting roughly 50,000 patients in the United States. The company’s success will be tied to the scientific progress of simufilam in this new indication, the strength of its intellectual property, and its ability to navigate regulatory and financial risks as a pre-revenue company. Securing a credible scientific and regulatory path forward, while managing expenses and legal liabilities, is central to its business model.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool